预约演示
更新于：2025-04-17
Dexibuprofen
右布洛芬
更新于：2025-04-17
概要
基本信息
原研机构- |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 奥地利 (2000-07-27), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-JTQLQIEISA-N |
CAS号51146-56-6 |
关联
23
项与 右布洛芬 相关的临床试验ChiCTR2500097383
A multi-center, randomized, and positive-drug parallel controlled prospective clinical study to evaluate the efficacy and safety of dexibuprofen in the treatment of children with fever caused by influenza
ChiCTR2400093489
Evaluation of the safety and efficacy of dexibuprofen in improving fever symptoms in children aged 6 months to 3 years: a multicenter post marketing clinical study
CTR20242540
JC002餐后比较药代动力学临床试验
100 项与 右布洛芬 相关的临床结果
登录后查看更多信息
100 项与 右布洛芬 相关的转化医学
登录后查看更多信息
100 项与 右布洛芬 相关的专利（医药）
登录后查看更多信息
1,789
项与 右布洛芬 相关的文献（医药）2025-04-01Science China-Chemistry
Tandem asymmetric propargylic amination/carboxylative cyclization reaction to chiral 5-methylidene-2-oxazolidinones using CO2 as C1 synthon
作者: Zhou, Jian ; Zhang, Zheng ; Sun, Ying ; Tang, Yun-Hao ; Yang, Yi-Zhuo ; Zhang, Zhi-Hao ; Zhou, Feng
We report a tandem asym. Cu-catalyzed propargylic amination (ACPA)/Ag-catalyzed carboxylative cyclization (SCC) with CO2 to 5-methylidene-2-oxazolidinones, even with tetrasubstituted stereocenters.By varying pyridine bisoxazoline (PYBOX) ligands, a general and highly enantioselective ACPA of unprecedentedly broad scope of secondary propargylic acetates and primary amines is achieved.Both α-aryl and α-aliphatic propargylic acetates could react with either aromatic or aliphatic primary amines to give the corresponding N-aryl or N-aliphatic ethynylamines with α-aliphatic or α-aryl groups in over 90% ee for use in the next step.The key to developing this one-pot sequence is to use a chelator triethylenetetramine (TETA) to mask the copper ion, to avoid its neg. effect on Ag-catalyzed cyclization, while releasing PYBOX to activate the silver catalyst.With the methylidene moiety, these oxazolidinones can be readily elaborated.The value of the sequence is further shown by the catalytic enantioselective total synthesis of (-)-cytoxazone and the potent ezetimibe analog.
2025-03-04ADVANCED SYNTHESIS & CATALYSIS
Palladium‐Catalyzed Cyclization Amination of Propargylamine and 1,3‐Dienes
作者: Wu, Wanqing ; Yao, Biao ; Xiong, Wenfang ; Jiang, Huanfeng
Abstract:
A novel and efficient palladium‐catalyzed cyclization amination of propargylamines and 1,3‐dienes is reported for the first time, yielding a series of chloromethylene pyrrolidines with high efficiency and excellent selectivity. This method was successfully applied to the late‐stage modification of natural products and drug molecules, providing molecular backbones with potential applications. The reaction was shown to achieve regioselective modulation of the product molecules through the resonance between the solvent and allylpalladium. Additionally, the E‐form products were found to be thermodynamically stable.
2025-03-01COLLOIDS AND SURFACES B-BIOINTERFACES
Dexibuprofen loaded into nanoemulsion based gel for topical application – In vitro characterization and in vivo anti-inflammatory evaluation
Article
作者: Irfan, Muhammad ; Khalid, Ikrima ; Shah, Pervaiz Akhtar ; Asghar, Sajid ; Munir, Muhammad Rehan ; Asif, Muhammad ; Khan, Ikram Ullah ; Munir, Rabia ; Albekairi, Norah A ; Khalid, Syed Haroon ; Kamal, Yousaf ; Alshammari, Abdulrahman
Arthritic disease is one of the most common diseases in adults and a leading cause of joint degeneration. Dexibuprofen (DEX) is routinely used for the treatment of rheumatoid arthritis, acute postoperative pain, primary dysmenorrheal, and in lower back pain. However, it is poorly water soluble with compromised bioavailability, and hence has limited therapeutic activity. In order to overcome these issues, we studied the formulation and characterization of nanoemulsion based system i.e nanoemulgel of DEX. This study aimed to prepare topical nanoemulgel containing 2 % DEX and solubility-enhanced DEX via ternary inclusion complexation (DEX-SE-T) and to compare it with commercially available 5 % Ibuprofen gel as there is no topical formulation of DEX is available in the market currently. A pseudoternary phase diagram was constructed using the spontaneous water titration method. Blank and drug-loaded nanoemulgel were prepared using a high-speed homogenization method. All the formulations were evaluated in terms of particle size, pH, conductivity, viscosity, zeta potential, and ex vivo drug permeation. DEX loaded nanoemulgel yield enhanced in vitro skin permeation than the commercially available 5 % ibuprofen gel. The optimized nanoemulgel formulation (DEX-SE-T) was tested in in vivo anti-inflammatory models including cotton pellets-induced abdominal granuloma (chronic inflammation) and carrageenan-induced paw edema (acute inflammation). DEX-SE-T loaded nanoemulgel has improved in vivo anti-inflammatory activity as compared to ibuprofen gel. DEX-SE-T could be a promising option for effective topical treatment of inflammatory conditions.
100 项与 右布洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 炎症 | 韩国 | 2007-12-31 | |
| 发热 | 中国 | 2001-01-01 | |
| 骨关节炎 | 中国 | - | 2001-01-01 |
| 类风湿关节炎 | 中国 | - | 2001-01-01 |
| 疼痛 | 奥地利 | 2000-07-27 | |
| 疼痛 | 意大利 | 2000-07-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床2期 | 中国 | 2021-07-13 | |
| 镇痛 | 临床2期 | 中国 | 2021-07-13 | |
| 麻醉 | 临床2期 | 中国 | 2020-11-16 | |
| 麻醉 | 临床2期 | 中国 | 2020-11-16 | |
| 急性疼痛 | 临床2期 | 美国 | 2018-01-12 | |
| 肌痛 | 临床2期 | 美国 | 2015-01-01 | |
| 痛经 | 临床1期 | 中国 | 2023-05-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 251 | (Active Arm) | 顧簾壓餘築簾築蓋憲壓(鏇廠選膚觸餘鹽鬱鏇鹹) = 觸壓蓋鬱膚遞鹽遞憲網 鬱壓蓋蓋構積網壓襯淵 (艱齋艱選淵獵蓋夢製餘, 31.311) 更多 | - | 2022-01-25 | ||
Vehicle (Placebo Arm) | 顧簾壓餘築簾築蓋憲壓(鏇廠選膚觸餘鹽鬱鏇鹹) = 積窪齋蓋齋衊夢壓繭遞 鬱壓蓋蓋構積網壓襯淵 (艱齋艱選淵獵蓋夢製餘, 29.763) 更多 | ||||||
临床3期 | 263 | 繭網齋鬱觸積範選鹽艱(遞願築構網網齋夢積夢) = 鑰襯憲獵壓窪鹽窪鬱鏇 淵夢願淵製憲鑰餘壓夢 (衊構選醖壓壓範醖鏇築 ) | - | 2018-06-23 | |||
繭網齋鬱觸積範選鹽艱(遞願築構網網齋夢積夢) = 廠築簾壓憲選憲夢鹽壓 淵夢願淵製憲鑰餘壓夢 (衊構選醖壓壓範醖鏇築 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用